Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

被引：0

作者：

Loree, Jonathan M.

Topham, James T.

Kennecke, Hagen Fritz

Feilotter, Harriet

Lee, Young S.

Virk, Shakeel

Kopetz, Scott

Duose, Dzifa Yawa

Manyam, Ganiraju C.

Morris, Jeffrey S.

Maru, Dipen M.

Renouf, Daniel

Jonker, Derek J.

Tu, Dongsheng

O'Callaghan, Christopher J.

Chen, Eric Xueyu

机构：

[1] Genome Sci Ctr, Vancouver, BC, Canada

[2] Providence Canc Inst, Portland, OR USA

[3] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada

[4] AstraZeneca, Translat Med, Gaithersburg, MD USA

[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA

[8] Univ Penn, Philadelphia, PA USA

[9] MD Anderson Canc Ctr, Houston, TX USA

[10] Univ British Columbia, Vancouver, BC, Canada

[11] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada

[12] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3551

引用

页数：1

共 50 条

[31] Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
Chen, Eric X.
Jonker, Derek J.
Loree, Jonathan M.
Kennecke, Hagen F.
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aucoin, Nathalie
Aubin, Francine
Koski, Sheryl L.
Wei, Alice C.
Magoski, Nadine M.
Tu, Dongsheng
O'Callaghan, Chris J.
JAMA ONCOLOGY, 2020, 6 (06) : 831 - 838
[32] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Lonardi, Sara
Falcone, Alfredo
Miron, Maria Luisa Limon
Saunders, Mark P.
Sobrero, Alberto F.
Park, Young Suk
Monteagudo, Reyes Ferreiro
Hong, Yong Sang
Tomasek, Jiri
Taniguchi, Hiroya
Ciardiello, Fortunato
Sassi, Mouna
Peil, Barbara
Hastedt, Claudia
Studeny, Matus
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[33] TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial
Karthaus, M.
Van Cutsem, E.
Mayer, R. J.
Ohtsu, A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 197 - 198
[34] Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Van Cutsem, Eric
Peeters, Marc
Siena, Salvatore
Humblet, Yves
Hendlisz, Alain
Neyns, Bart
Canon, Jean-Luc
Van Laethem, Jean-Luc
Maurel, Joan
Richardson, Gary
Wolf, Michael
Amado, Rafael G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1658 - 1664
[35] TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.
Mayer, Robert J.
Ohtsu, Atsushi
Yoshino, Takayuki
Falcone, Alfredo
Garcia-Carbonero, Rocio
Tabernero, Josep
Sobrero, Alberto F.
Peeters, Marc
Benedetti, Fabio
Makris, Lukas
Ambe, Hiroshi
Zaniboni, Alberto
Shimada, Yasuhiro
Yamazaki, Kentaro
Komatsu, Yoshito
Hochster, Howard S.
Lenz, Heinz-Josef
Ben Tran
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[36] Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).
Karthaus, Meinolf
Welslau, Manfred
Riera-Knorrenschild, Jorge
Kretzschmar, Albrecht
Vehling-Kaiser, Ursula
Mahlberg, Rolf
Pelz, Henning
Lindig, Udo
von Weikersthal, Ludwig Fischer
Heinemann, Volker
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[37] Impact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
Loree, J. M.
Jonker, D. J.
Feilotter, H.
Kennecke, H. F.
Brohawn, P. Z.
Banks, K.
Quinn, K.
Tu, D.
O'Callaghan, C.
Chen, E. X.
ANNALS OF ONCOLOGY, 2019, 30 : 200 - +
[38] The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).
Jonker, Derek J.
Nott, Louise M.
Yoshino, Takayuki
Li, Chiang
Gill, Shariene
Shapiro, Jeremy David
Ohtsu, Atsushl
Zalcberg, John Raymond
Vickers, Michael M.
Slims, John
Wei, Alice Chia-Chi
Mittmann, Nicole
Magoski, Nadine M.
Murray, Yvonne
Tsobanis, Eric
Tu, Dongsheng
Kerstein, David
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[39] PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D plus T) versus standard of care chemotherapy (SoC)
Bellmunt, J.
Powles, T. B.
Van der Heijden, M. S.
Galsky, M. D.
He, P.
Wang, Z.
Xiao, F.
Jones, F.
Scott, M.
Walker, J.
Angra, N.
Gupta, A.
Drakaki, A.
Kimura, G.
Mizokami, A.
Wildsmith, S.
ANNALS OF ONCOLOGY, 2021, 32 : S716 - S717
[40] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC: PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRAS TUMOR STATUS
Odom, D.
Devercelli, G.
Bennett, L.
Peeters, M.
Wolf, M.
Amado, R.
VALUE IN HEALTH, 2008, 11 (06) : A487 - A487

← 1 2 3 4 5 →